JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $202
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on Jazz Pharmaceuticals and raises the price target from $190 to $202.
August 19, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has increased its price target for Jazz Pharmaceuticals from $190 to $202 while maintaining an Overweight rating, indicating a positive outlook.
The increase in price target from $190 to $202 by JP Morgan, along with maintaining an Overweight rating, suggests a positive sentiment towards Jazz Pharmaceuticals. This is likely to have a favorable impact on the stock price in the short term as it reflects confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100